- Home
- ADVM
as 06-20-2025 4:00pm EST
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 47.4M | IPO Year: | 2014 |
| Target Price: | $26.40 | AVG Volume (30 days): | 186.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.78 - $10.14 | Next Earning Date: | 08-11-2025 |
| Revenue: | $1,000,000 | Revenue Growth: | -72.22% |
| Revenue Growth (this year): | -80.62% | Revenue Growth (next year): | 18.82% |
Stock Insider Trading Activity of Adverum Biotechnologies Inc. (ADVM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Seyedkazemi Setareh | ADVM | CHIEF DEVELOPMENT OFFICER | May 15 '25 | Sell | $2.00 | 924 | $1,848.00 | 13,768 | |
| Fischer Laurent | ADVM | CEO, PRESIDENT AND DIRECTOR | May 15 '25 | Sell | $2.00 | 9,126 | $18,252.00 | 87,488 | |
| Soparkar Peter | ADVM | CHIEF OPERATING OFFICER | May 15 '25 | Sell | $2.00 | 2,960 | $5,920.00 | 39,154 | |
| Leonard Braden Michael | ADVM | 10% Owner | Apr 22 '25 | Buy | $2.99 | 350,000 | $1,048,950.00 | 3,057,526 | |
| Leonard Braden Michael | ADVM | 10% Owner | Mar 31 '25 | Buy | $4.21 | 34,775 | $147,075.63 | 3,057,526 | |
| Leonard Braden Michael | ADVM | 10% Owner | Mar 26 '25 | Buy | $5.11 | 111,000 | $566,791.62 | 3,057,526 |
Latest Adverum Biotechnologies Inc. News
ADVM Breaking Stock News: Dive into ADVM Ticker-Specific Updates for Smart Investing
GlobeNewswire
16 days ago
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance Video
20 days ago
Will Tesla have to play catch up to Waymo's robotaxis?
Yahoo Finance
20 days ago
Why Scott Bessent wants to make it easier for banks to own Treasurys
GlobeNewswire
20 days ago
EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry
GlobeNewswire
20 days ago
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
PR Newswire
20 days ago
Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population
CNW Group
20 days ago
Statement by Minister Guilbeault on Portuguese Heritage Month
AFP
20 days ago
Man Utd sign Brazil forward Cunha from Wolves
Compare ADVM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADVM Adverum Biotechnologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.